Strategic R&D Partnerships NantWorks has established collaborations with leading academic institutions like Wits University and the South African Medical Research Council, indicating an openness to joint ventures, research collaborations, and technology licensing opportunities in biotech, immunology, and infectious diseases.

Vaccine Manufacturing Capacity The company has recently invested over 200 million dollars to build a large-scale vaccine production plant aiming to produce one billion vaccines annually by 2025, presenting significant opportunities for suppliers of manufacturing equipment, raw materials, and distribution systems.

Healthcare Innovation Focus NantWorks actively invests in developing advanced therapeutics including cancer vaccines and cell-based therapies, positioning it as a potential customer for innovative biotech tools, laboratory automation, and clinical trial support technologies.

Technology and Data Infrastructure With recent asset acquisitions such as data centers and the use of various tech stack tools, NantWorks demonstrates ongoing needs for advanced data management, cybersecurity, and cloud infrastructure solutions to support biotech R&D and operational activities.

Market Expansion and IP Development The company's efforts to expand immunotherapy and vaccine capabilities, coupled with ongoing patent litigations, suggest opportunities for legal, licensing, and intellectual property management services, as well as strategic consulting for competitive positioning in biotech markets.